These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 10718088)
41. Estimation of Direct Medical Costs Related to Chronic Hepatitis C: A Rationale for Early Antiviral Therapy. Kim DY Gut Liver; 2017 Nov; 11(6):745-746. PubMed ID: 29081211 [No Abstract] [Full Text] [Related]
42. Pericarditis after therapy with interferon-alpha for chronic hepatitis C. Boonen A; Stockbrügger RW; van der Linden S Clin Rheumatol; 1999; 18(2):177-9. PubMed ID: 10357129 [TBL] [Abstract][Full Text] [Related]
44. Newest Treatments for Hepatitis C: How Can We Manage Sustainability? Messori A Clin Infect Dis; 2015 Dec; 61(12):1891-2. PubMed ID: 26261204 [No Abstract] [Full Text] [Related]
45. Reply to Messori. Rein DB Clin Infect Dis; 2015 Dec; 61(12):1892-3. PubMed ID: 26261202 [No Abstract] [Full Text] [Related]
46. Some considerations about cardiac toxicity of combination therapy for chronic hepatitis C. Karbasi-Afshar R; Saburi A Hepat Mon; 2013 May; 13(5):e8962. PubMed ID: 23967024 [No Abstract] [Full Text] [Related]
47. Double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis C. Levent F Hepatol Res; 2011 Feb; 41(2):197. PubMed ID: 21269390 [No Abstract] [Full Text] [Related]
48. [Interferon combination and interferon-free anti-viral therapy]. Imamura M; Chayama K Nihon Shokakibyo Gakkai Zasshi; 2014 Sep; 111(9):1747-53. PubMed ID: 25195959 [No Abstract] [Full Text] [Related]
49. Making it happen: managed care considerations in vanquishing hepatitis C. McHutchison JG; Bacon BR; Owens GS Am J Manag Care; 2007 Dec; 13 Suppl 12():S327-36; quiz S337-40. PubMed ID: 18095781 [TBL] [Abstract][Full Text] [Related]
50. What is (cost) effective in patients with chronic hepatitis C virus infection? Zeuzem S Eur J Gastroenterol Hepatol; 2001 May; 13(5):473-6. PubMed ID: 11396523 [TBL] [Abstract][Full Text] [Related]
51. [Does combination therapy of chronic viral hepatitis C with interferon-alpha and ribavirin approach financial limits?]. Steimann RU; Bode JC Versicherungsmedizin; 2000 Mar; 52(1):24-7. PubMed ID: 10718088 [TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Wong JB; Poynard T; Ling MH; Albrecht JK; Pauker SG Am J Gastroenterol; 2000 Jun; 95(6):1524-30. PubMed ID: 10894590 [TBL] [Abstract][Full Text] [Related]
53. Economic evaluation of chronic hepatitis C treatment by interferon-ribavirin combination therapy in Belgium. Delwaide J Acta Gastroenterol Belg; 2002; 65(4):233-6. PubMed ID: 12619432 [TBL] [Abstract][Full Text] [Related]
54. Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C. Wong JB; Davis GL; Pauker SG Am J Med; 2000 Apr; 108(5):366-73. PubMed ID: 10759092 [TBL] [Abstract][Full Text] [Related]
55. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Younossi ZM; Singer ME; McHutchison JG; Shermock KM Hepatology; 1999 Nov; 30(5):1318-24. PubMed ID: 10534357 [TBL] [Abstract][Full Text] [Related]
56. Cost-effectiveness of interferon alfa 2b and ribavirin in the treatment of chronic hepatitis C. Kim WR; Poterucha JJ; Gross JB Hepatology; 2000 Mar; 31(3):807-8. PubMed ID: 10722315 [No Abstract] [Full Text] [Related]